Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity

NCT04788511 on ClinicalTrials.gov · last registry update 2025-12-05

Finished 18 April 2023, after enrolling 529 people. Primary outcome, as filed: Change in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS). semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P3
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Novo Nordisk A/S
Sponsor type: Industry
Enrollment: 529
Started: 2021-03-16
Primary completion: 2023-04-18 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS)

Conditions studied

Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.